医学临床研究
  2025年4月5日 星期六           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2024, Vol. 41 Issue (8): 1219-1221    DOI: 10.3969/j.issn.1671-7171.2024.08.029
  论著 本期目录 | 过刊浏览 | 高级检索 |
沙库巴曲缬沙坦联合匹伐他汀治疗冠心病合并心力衰竭的临床疗效
费优生, 高洁*, 张超, 徐俊蛟, 赵成刚
上海市嘉定区南翔医院,上海 201802
Clinical Efficacy of Sacubitril Valsartan Combined with Pitavastatin in the Treatment of Coronary Heart Disease Complicated with Heart Failure
FEI Yousheng, GAO Jie, ZHANG Chao, et al
Nanxiang Hospital, Jiading District, Shanghai 201802
全文: PDF (1185 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨沙库巴曲缬沙坦联合匹伐他汀治疗冠心病(CHD)合并心力衰竭(HF)的临床疗效。【方法】回顾性分析2020年2月至2022年2月本院收治的82例CHD合并HF患者的临床资料,根据治疗方法不同将其分为对照组(在常规治疗的基础上给予匹伐他汀治疗)和观察组(在对照组的基础上给予沙库巴曲缬沙坦治疗),每组41例。比较两组临床疗效、心功能指标[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)]、6 min步行实验(6MWT)距离、生活质量[明尼苏达心衰生活质量量表(LHFQ)评分],统计治疗期间不良反应发生情况。【结果】观察组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组LVEF高于治疗前,LVEDD、LVESD低于治疗前,且观察组与对照组比较,差异均有统计学意义(P<0.05)。治疗后,两组6MWT距离大于治疗前,LHFQ评分低于治疗前,且观察组与对照组比较,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。【结论】沙库巴曲缬沙坦联合匹伐他汀治疗CHD合并HF疗效较好,可显著改善患者心功能,提高患者生活质量,且安全性高。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
关键词 冠心病心力衰竭缬沙坦羟甲基戊二酰基CoA还原酶抑制剂    
Abstract:【Objective】To investigate the clinical efficacy of sacubitril valsartan combined with pitavastatin in the treatment of coronary heart disease (CHD) with heart failure (HF).【Methods】A retrospective analysis was conducted on the clinical data of 82 patients with CHD combined with HF admitted to our hospital from February 2020 to February 2022. According to the treatment method, they were divided into the control group (treated with pitavastatin in addition to conventional treatment) and the observation group (treated with sacubitril in addition to the control group), with 41 patients in each group. Two groups were compared in terms of clinical efficacy, cardiac function indicators [left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD)], 6-minute walk test (6MWT) distance, and quality of life [Minnesota Heart Failure Quality of Life Scale (LHFQ score)], and the incidence of adverse reactions during treatment was statistically analyzed. 【Results】The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, LVEF in both groups was higher than before treatment, while LVEDD and LVESD were lower than before treatment. The differences between the observation group and the control group were statistically significant (P<0.05). After treatment, the distance between the two groups of 6MWT distarce was greater than before treatment, and the LHFQ score was lower than before treatment. Moreover, the difference between the observation group and the control group was statistically significant (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】The combination of sacubitril valsartan and pitavastatin has a good therapeutic effect on CHD complicated with HF, significantly improving patients' cardiac function, enhancing their quality of life, and has high safety.
Key wordsCoronary Disease    Heart Failure    Valsartan    Hydroxymethylglutaryl-CoA Reductase Inhibitors
收稿日期: 2023-08-01     
中图分类号:  R541.4  
通讯作者: * E-mail:gaojie690831@163.com   
引用本文:   
费优生, 高洁, 张超, 徐俊蛟, 赵成刚. 沙库巴曲缬沙坦联合匹伐他汀治疗冠心病合并心力衰竭的临床疗效[J]. 医学临床研究, 2024, 41(8): 1219-1221.
FEI Yousheng, GAO Jie, ZHANG Chao, et al. Clinical Efficacy of Sacubitril Valsartan Combined with Pitavastatin in the Treatment of Coronary Heart Disease Complicated with Heart Failure. JOURNAL OF CLINICAL RESEARCH, 2024, 41(8): 1219-1221.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.08.029     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I8/1219
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn